A well-known collaborator with Eli Lilly – BioAge Labs is focusing on developing an anti-obesity drug for the elderly "by targeting the biology of human ageing", the biopharmaceutical start-up said.

BioAge Labs, Inc. (BIOA) has received a new Buy rating, initiated by Morgan Stanley analyst, Jeffrey Hung. Jeffrey Hung’s rating is based on several promising developments at BioAge Labs, Inc ...

Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting ...